Immunotherapy is a milestone in the treatment of poor-prognosis pediatric acute
lymphoblastic leukemia (ALL) and is expected to improve treatment outcomes and reduce …

Background The dramatic increase in the number of childhood cancer survivors over the last
60 years has made monitoring and minimising long term side effects of cancer treatment …

Vincristine (VCR) is the first-line chemotherapeutic medication often co-administered with
other drugs to treat childhood acute lymphoblastic leukemia. Dose-dependent neurotoxicity …

Skeletal muscle (muscle) is essential for physical health and for metabolic integrity, with
sarcopenia (progressive muscle mass loss and weakness), a precursor of aging and chronic …

Peripheral neuropathy is a well recognised treatment-related toxicity in children with cancer,
associated with exposure to neurotoxic chemotherapy agents. Acute damage can occur in …

Children treated for cancer are at increased risk of developing chronic health conditions,
some of which may manifest during or soon after treatment while others emerge many years …

Purpose: Children treated with vincristine often develop chemotherapy-induced peripheral
neuropathy (CIPN), but effects of CIPN on gait have not been reported. Methods: Gait …

Objective Vincristine is a mainstay treatment for paediatric cancers, particularly acute
lymphoblastic leukemia (ALL), with common toxicity including vincristine-induced peripheral …

Neuropathic pain in pediatric oncology can be caused by distinct lesions or disease
processes affecting the somatosensory system, including chemotherapy-related neuronal …

Purpose Chemotherapy‐induced peripheral neuropathy (CIPN) is a frequent side effect of
pediatric cancer treatment. The presentation of CIPN, trajectory and completeness of …